Array gets positive rating from analyst firm, announces latest trial results
BOULDER — Analyst firm Piper Jaffray has named Array Biopharma (Nasdaq: ARRY) overweight and set a price point for $21 per share.
The firm says Array reported an “impressive” one-year survival rate of 62 percent of its latest BEACON phase 3 clinical trial. The trial evaluated the triple combination of encorafenib, binimetini, and cetuximab in patients with a specific mutation of colorectal cancer.
Array announced its results at a June 23 presentation at the World Congress on Gastrointestinal Cancer in Spain.
SPONSORED CONTENT
Business Cares: April 2024
In Colorado, 1 in 3 women, 1 in 3 men and 1 in 2 transgender individuals will experience an attempted or completed sexual assault in their lifetime. During April, we recognize Sexual Assault Awareness Month with the hopes of increasing conversations about this very important issue.
Enrollment in a randomized portion of the BEACON trial is ongoing.
BOULDER — Analyst firm Piper Jaffray has named Array Biopharma (Nasdaq: ARRY) overweight and set a price point for $21 per share.
The firm says Array reported an “impressive” one-year survival rate of 62 percent of its latest BEACON phase 3 clinical trial. The trial evaluated the triple combination of encorafenib, binimetini, and cetuximab in patients with a specific mutation of colorectal cancer.
Array announced its results at a June 23 presentation at the World Congress on Gastrointestinal Cancer in Spain.
Enrollment in a randomized portion of the BEACON trial is ongoing.
…THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
